Human Genome shares up 200%
Steve Ladurantaye
Now that's a pop - shares in Human Genome HGSI-Qgained more than 200 per cent Monday morning after it said that a drug it's developing with GlaxoSmithKline for lupus did well in clinical trials.
The shares gained $6.88 (U.S.) to $10.21 in early trade - a gain of 208 per cent. The company said the drug was "generally well tolerated with adverse events occurring at rates comparable to those of the groups treated with placebo. GlaxoSmithKline shares gained 2.37 per cent.
The company, based in Rockdale, MD, traded near $11 last October, but had slumped as low as 52 cents when the market set fresh lows in March.